ASCO 2022 Conference Coverage


 

ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment for Unresectable RAS and BRAF Wild-Type mCRC: Results of the Phase III Randomized TRIPLETE Study by GONO

191 views
June 10, 2022
Comments 0
Login to view comments. Click here to Login